JO2359B1 - Benzathene derivatives as agents for modulation of GABA A receptor - Google Patents

Benzathene derivatives as agents for modulation of GABA A receptor

Info

Publication number
JO2359B1
JO2359B1 JO2001183A JOP20010183A JO2359B1 JO 2359 B1 JO2359 B1 JO 2359B1 JO 2001183 A JO2001183 A JO 2001183A JO P20010183 A JOP20010183 A JO P20010183A JO 2359 B1 JO2359 B1 JO 2359B1
Authority
JO
Jordan
Prior art keywords
gaba
receptor modulators
benzodiazepine derivatives
receptor
compounds
Prior art date
Application number
JO2001183A
Other languages
Arabic (ar)
English (en)
Inventor
ماسيادري رافيللو
ويليام ثوماس اندرو
ويتشمان جيورجن
Original Assignee
اف . هوفمان- لاروش أيه جي
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by اف . هوفمان- لاروش أيه جي filed Critical اف . هوفمان- لاروش أيه جي
Application granted granted Critical
Publication of JO2359B1 publication Critical patent/JO2359B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JO2001183A 2000-11-16 2001-11-12 Benzathene derivatives as agents for modulation of GABA A receptor JO2359B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00124332 2000-11-16

Publications (1)

Publication Number Publication Date
JO2359B1 true JO2359B1 (en) 2006-12-12

Family

ID=8170315

Family Applications (1)

Application Number Title Priority Date Filing Date
JO2001183A JO2359B1 (en) 2000-11-16 2001-11-12 Benzathene derivatives as agents for modulation of GABA A receptor

Country Status (40)

Country Link
US (1) US6743789B2 (https=)
EP (1) EP1337535B1 (https=)
JP (1) JP4088151B2 (https=)
KR (1) KR100504300B1 (https=)
CN (1) CN1191255C (https=)
AR (1) AR031345A1 (https=)
AT (1) ATE268776T1 (https=)
AU (2) AU1700702A (https=)
BG (1) BG107817A (https=)
BR (1) BR0115393A (https=)
CA (1) CA2427576C (https=)
CZ (1) CZ295256B6 (https=)
DE (1) DE60103776T2 (https=)
DK (1) DK1337535T3 (https=)
EC (1) ECSP034607A (https=)
ES (1) ES2220831T3 (https=)
GC (1) GC0000375A (https=)
GT (1) GT200100230A (https=)
HR (1) HRP20030360A2 (https=)
HU (1) HUP0303281A3 (https=)
IL (1) IL155813A0 (https=)
JO (1) JO2359B1 (https=)
MA (1) MA26962A1 (https=)
MX (1) MXPA03004251A (https=)
MY (1) MY141675A (https=)
NO (1) NO324706B1 (https=)
NZ (1) NZ525413A (https=)
PA (1) PA8532401A1 (https=)
PE (1) PE20020583A1 (https=)
PL (1) PL362925A1 (https=)
PT (1) PT1337535E (https=)
RU (1) RU2278865C2 (https=)
SI (1) SI1337535T1 (https=)
SK (1) SK7232003A3 (https=)
TR (1) TR200402073T4 (https=)
TW (1) TWI239333B (https=)
UY (1) UY27026A1 (https=)
WO (1) WO2002040487A2 (https=)
YU (1) YU35603A (https=)
ZA (1) ZA200303435B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
JP4616770B2 (ja) * 2003-06-19 2011-01-19 第一三共株式会社 選択的なアミノ置換基導入法
US20050176680A1 (en) 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
CA2577060A1 (en) 2004-08-13 2006-02-23 Amgen Inc. Substituted benzofused heterocycles
WO2006040038A1 (en) * 2004-10-12 2006-04-20 F.Hoffmann-La Roche Ag Imidazo [1, 5-a]triazolo[1, 5-d]benzodiazepine derivatives for the treatment of cognitive disorders
ES2399439T3 (es) * 2004-10-20 2013-04-01 F. Hoffmann-La Roche Ag Derivados de imidazo-benzodiazepina
AU2005299031B2 (en) * 2004-10-20 2011-11-10 F. Hoffmann-La Roche Ag Halogen substituted benzodiazepine derivatives
BRPI0515800A (pt) 2004-12-14 2008-08-05 Hoffmann La Roche imidazo-benzodiazepinas tetracìclicas como moduladores de receptores de gaba
US8510055B2 (en) 2005-08-03 2013-08-13 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
EP1924712B1 (en) * 2005-08-03 2018-10-03 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
KR101009860B1 (ko) * 2005-10-11 2011-01-19 에프. 호프만-라 로슈 아게 이미다조 벤조다이아제핀 유도체
US20070112017A1 (en) * 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US9156836B2 (en) * 2008-05-16 2015-10-13 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate HSP90 activity
KR101385433B1 (ko) * 2008-11-18 2014-04-14 에프. 호프만-라 로슈 아게 다이하이드로테트라아자벤조아줄렌의 알킬사이클로헥실에터
HRP20131067T1 (hr) * 2008-11-28 2013-12-06 F. Hoffmann - La Roche Ag Arilcikloheksileteri od dihidrotetraazabenzoazulena za primjenu kao antagonista receptora vazopresina v1a
CU20090172A6 (es) 2009-10-09 2011-10-05 Facultad De Quimica Universidad De La Habana Sistemas tricíclicos y tetracíclicos con actividad sobre el sistema nervioso central y vascular
EP3034079B1 (en) 2010-11-15 2018-01-10 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
CA2885148A1 (en) * 2012-09-21 2014-03-27 Uwm Research Foundation, Inc. Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma
EP3083569B1 (en) * 2013-12-20 2022-01-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP6987384B2 (ja) * 2015-06-19 2021-12-22 エージンバイオ, インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
US10059718B2 (en) * 2016-01-04 2018-08-28 Tabomedex Biosciences, LLC Fused quadracyclic compounds, compositions and uses thereof
US10973479B2 (en) 2016-05-16 2021-04-13 Canon Medical Systems Corporation X-ray diagnosis apparatus, X-ray diagnosis apparatus controlling method, and X-ray diagnosis system
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) * 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
KR102512548B1 (ko) 2017-12-22 2023-03-22 삼성디스플레이 주식회사 유기 전계 발광 소자 및 유기 전계 발광 소자용 함질소 화합물
US11414425B2 (en) 2018-06-19 2022-08-16 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
KR102151969B1 (ko) * 2019-12-11 2020-09-04 주식회사 지투비 투과도 가변창의 제조방법 및 그에 의해 제조된 투과도 가변창
CN112979658B (zh) * 2021-02-22 2022-05-31 南湖实验室 一种氟马西尼的制备方法
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK174086D0 (da) 1986-04-16 1986-04-16 Ferrosan As Nye benzodiazepinderivater samt fremgangsmaade til fremstilling af samme
TW201311B (https=) 1991-06-17 1993-03-01 Hoffmann La Roche

Also Published As

Publication number Publication date
MY141675A (en) 2010-06-15
ATE268776T1 (de) 2004-06-15
HUP0303281A3 (en) 2005-05-30
MA26962A1 (fr) 2004-12-20
PA8532401A1 (es) 2002-08-26
DE60103776T2 (de) 2005-07-14
CN1191255C (zh) 2005-03-02
PT1337535E (pt) 2004-09-30
CA2427576C (en) 2007-11-06
BG107817A (bg) 2004-07-30
CN1474820A (zh) 2004-02-11
NO324706B1 (no) 2007-12-03
WO2002040487A3 (en) 2002-09-26
AR031345A1 (es) 2003-09-17
CA2427576A1 (en) 2002-05-23
EP1337535A2 (en) 2003-08-27
RU2278865C2 (ru) 2006-06-27
CZ20031597A3 (cs) 2003-11-12
DK1337535T3 (da) 2004-10-25
HRP20030360A2 (en) 2005-04-30
AU1700702A (en) 2002-05-27
DE60103776D1 (de) 2004-07-15
RU2003116895A (ru) 2005-02-20
AU2002217007B2 (en) 2006-11-30
KR100504300B1 (ko) 2005-07-28
ES2220831T3 (es) 2004-12-16
GC0000375A (en) 2007-03-31
JP4088151B2 (ja) 2008-05-21
IL155813A0 (en) 2003-12-23
HUP0303281A2 (hu) 2004-01-28
SI1337535T1 (en) 2004-10-31
ZA200303435B (en) 2004-08-05
UY27026A1 (es) 2002-06-20
YU35603A (sh) 2006-05-25
US20020103371A1 (en) 2002-08-01
SK7232003A3 (en) 2004-03-02
NZ525413A (en) 2005-02-25
TR200402073T4 (tr) 2004-10-21
EP1337535B1 (en) 2004-06-09
CZ295256B6 (cs) 2005-06-15
ECSP034607A (es) 2003-06-25
PE20020583A1 (es) 2002-07-06
NO20032208D0 (no) 2003-05-15
JP2004517070A (ja) 2004-06-10
NO20032208L (no) 2003-05-15
TWI239333B (en) 2005-09-11
BR0115393A (pt) 2004-07-06
MXPA03004251A (es) 2003-09-22
PL362925A1 (en) 2004-11-02
US6743789B2 (en) 2004-06-01
WO2002040487A2 (en) 2002-05-23
KR20030045192A (ko) 2003-06-09
HK1062442A1 (en) 2004-11-05
GT200100230A (es) 2002-07-04

Similar Documents

Publication Publication Date Title
JO2359B1 (en) Benzathene derivatives as agents for modulation of GABA A receptor
AU3652102A (en) Compounds and their uses
BG103870A (en) Substituted benzopyran derivatives for the treatment of inflammations
AU5242000A (en) Nematicidal trifluorobutenes
MY132671A (en) Substituted 6,6-hetero-bicyclic derivatives
BG102976A (en) Method for the preparation of drospyrenon (6 beta,7 beta: 15 beta,16 beta - dimethylene-3-oxo-17 alpha -pregn-4-ene-21,17-carbolacton, drsp)as well as 7 alpha-(3-hydroxy-1-propyl)-(6 beta,7 beta: 15 beta,16 beta -dirmethylene-5 beta-androstan-3 beta,5,17 beta -triol (zk 92836) and (6 beta,7 beta: 15 beta,16 beta - dimethylene-5 beta-hydroxy-3-oxo-17 alpha -androstan-21, 17-carbolacton (90965) as intermediate compounds of the method
MY134559A (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis
AU7743001A (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
EP0911321A3 (en) Compounds for the treatment of osteoporosis
MXPA02009773A (es) Derivados de indolin-2-ona y su uso como ligandos de receptores de ocitocina.
MX9804588A (es) Uso de composiciones que comprenden blanqueador de halogeno para suavidad mejorada a la piel.
WO2003057145A3 (en) SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
IL117091A0 (en) Methylphenyloxazolidinone derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
WO1998058911A3 (en) Prostaglandin agonists
BG105197A (en) Polymorph form of a medicament
AU2001269063A1 (en) Shortened synthesis of 3,3-diarylpropylamine derivatives
MY133390A (en) Azabicyclic 5ht1 receptor ligands
UA66866C2 (uk) Синтез морфолінових похідних
BG103649A (en) Method for the preparation of eprosartan
AU7216498A (en) Inhibitors of the urokinase receptor
AU2002227895A1 (en) Sulphonamides for the treatment of central nervous system diseases
BG103650A (en) Method for the preparation of eprosartan
BG102229A (en) Endothelium receptor antagonists
AU2002336437A1 (en) Therapeutic uses of complement receptor 2